Efficient capture of high-quality data on outcomes of treatment for macular diseases: The fight retinal blindness! project

Retina

Volumn 34, Issue 1, 2014, Pages 188-195

  Gillies, Mark C ^a   Walton, Richard ^a   Liong, Julines ^b   Arnold, Jennifer J ^c   McAllister, Ian ^d   Morlet, Nigel ^e   Hunyor, Alex ^f   Guymer, Robyn ^g   Keeffe, Jill ^g   Essex, Rohan ^h   Herrera Bond, Amparo ^a   Glastonbury, Briony ^a   Simpson, Judy M ⁱ   Barthelmes, Daniel ^a,j  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Marsden Eye Specialists   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Retina Associates   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANBERRA HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Age related macular degeneration; Patient outcome registry; Postmarketing observational study; Vascular endothelial growth factor inhibitors

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; AUSTRALIA; BLINDNESS; COMPUTER PROGRAM; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MALE; NEW ZEALAND; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA DEGENERATION; RETINA MACULOPATHY; SWITZERLAND; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; BLINDNESS; DATA COLLECTION; FEMALE; HUMANS; INFORMATION CENTERS; MALE; ONLINE SYSTEMS; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; SOFTWARE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84891857602     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318296b271     Document Type: Article

References (27)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
4. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
5. Heier JS, Brown DM, Chong V, et al.; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119: 2537-2548.
6. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-1826.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
8. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, et al. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008;8:18.
9. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina 2011;31:1856-1862.
10. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
11. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
12. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207.
13. Derosa G, Maffioli P. Peroxisome proliferator-activated receptorgamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012;5: 272-281.
14. Glicklich RE, Dreyer NA. Registries for Evaluating Patient Outcomes: A User's Guide. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
15. Weih LM, Hassell JB, Keeffe J. Assessment of the impact of vision impairment. Invest Ophthalmol Vis Sci 2002;43:927-935.
16. NHMRC. When Does Quality Assurance in Health Care Require Independent Ethical Review? Advice to Institutions, Human Research Ethics Committees and Health Care Professionals. Sydney, Australia: NHMRC; 2003.
17. ACSQHC. Operating Principles and Technical Standards for Australian Clinical Quality Registries; 2008.
18. McNeil JJ, Evans SM, Johnson NP, Cameron PA. Clinical-quality registries: their role in quality improvement. Med J Aust 2010; 192:244-245.
19. R: A Language and Environment for Statistical Computing. 2006. Foundation for Statistical Computing, Vienna, Austria Available at: http://www.R-project. org. Accessed August 21, 2012.
20. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112: 500-509.
21. Sedrakyan A. Metal-on-metal failures-in science, regulation, and policy. Lancet 2012;379:1174-1176.
22. Kennedy L, Craig AM. Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation. Pharmacoeconomics 2004;22:551-568.
23. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011;2011: 405724.
24. Finger RP, Holz FG. Access to healthcare services for elderly patients with neovascular age-related macular degeneration [in German]. Ophthalmologe 2012;109:474-478.
25. Behndig A, Montan P, Stenevi U, et al. One million cataract surgeries: Swedish National Cataract Register 1992-2009. J Cataract Refract Surg 2011;37:1539-1545.
26. Lundstrom M, Barry P, Henry Y, et al. Evidence-based guidelines for cataract surgery: guidelines based on data in the European Registry of Quality Outcomes for Cataract and Refractive Surgery database. J Cataract Refract Surg 2012;3:1086-1093.
27. Williams KA, Lowe M, Bartlett C, et al. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 2008;86:1720-1724.